Clinical Study

Nrg-Hn007-An Open-Label, Phase III Study Of Platinum-Gemcitabine With Or Without Nivolumab In The First-Line Treatment Of Recurrent Or Metastatic Nasopharyngeal Carcinoma

Posted Date: May 5, 2021

  • Investigator: Muhammad Riaz
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The primary purpose of this study is to compare the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come back (recurrent) or spread to other places in the body (metastatic). The primary outcome measured will be overall survival.


Pathologically (Histologically Or Cytologically) Proven Diagnosis Of Npc That Has Recurred At Locoregional And/Or Distant Sites, Ecog Of 0-1, Adequate Organ Function Per Protocol. No Other Malignancy Within 3 Years, No Past Or Current Medical Disease Or Infection That May Impact A Patient's Ability To Adhere To Study Treatment, No Prior Anti-Cancer Treatment, No History Of Severe (Grade 3-4) Hypersensitivity Reaction To Any Monoclonal Antibody Including Nivolumab And/Or Any Of Its Excipients


Head And Neck Cancer, Nasopharyngeal

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.